TAE226

featured

WARNING: This product is for research use only, not for human or veterinary use.

Description:TAE226 is a novel and potent ATP competitive inhibitor of FAK and IGF-IR with potential anticancer activity. TAE226 can block FAK and IGF-IR signaling pathways. TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines. TAE226 induced a concentration-dependent decrease in cellular proliferation with an associated G(2) cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner. TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix.

Price and Availability

TAE226, purity > 98%, is in stock. The same day shipping out after order is received.

Chemical Structure

Theoretical Analysis

MedKoo Cat#: 406127Name: TAE226CAS#: 761437-28-9Chemical Formula: C23H25ClN6O3Exact Mass: 468.16767Molecular Weight: 468.936Elemental Analysis: C, 58.91; H, 5.37; Cl, 7.56; N, 17.92; O, 10.24

Synonym:NVPTAE226, NVP TAE226, NVP-TAE226, TAE226, TAE226, TAE 226

IUPAC/Chemical Name:2-((5-chloro-2-((2-methoxy-4-morpholinophenyl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide

InChi Key:UYJNQQDJUOUFQJ-UHFFFAOYSA-N

InChi Code:InChI=1S/C23H25ClN6O3/c1-25-22(31)16-5-3-4-6-18(16)27-21-17(24)14-26-23(29-21)28-19-8-7-15(13-20(19)32-2)30-9-11-33-12-10-30/h3-8,13-14H,9-12H2,1-2H3,(H,25,31)(H2,26,27,28,29)

SMILES Code:O=C(NC)C1=CC=CC=C1NC2=NC(NC3=CC=C(N4CCOCC4)C=C3OC)=NC=C2Cl

Technical Data

References

1: Kurio N, Shimo T, Fukazawa T, Okui T, Hassan NM,Honami T, Horikiri Y, Hatakeyama S, Takaoka M, Naomoto Y, Sasaki A.Anti-tumor effect of a novel FAK inhibitor TAE226 against human oralsquamous cell carcinoma. Oral Oncol. 2012 Nov;48(11):1159-70. doi:10.1016/j.oraloncology.2012.05.019. Epub 2012 Jul 4. PubMed PMID:22766511.

2: Hao HF, Takaoka M, Bao XH, Wang ZG, Tomono Y, Sakurama K, Ohara T,Fukazawa T, Yamatsuji T, Fujiwara T, Naomoto Y. Oral administration ofFAK inhibitor TAE226 inhibits the progression of peritonealdissemination of colorectal cancer. Biochem Biophys Res Commun. 2012 Jul13;423(4):744-9. doi: 10.1016/j.bbrc.2012.06.030. Epub 2012 Jun 13.PubMed PMID: 22705303.

3: Kurio N, Shimo T, Fukazawa T, Takaoka M, Okui T, Hassan NM, Honami T,Hatakeyama S, Ikeda M, Naomoto Y, Sasaki A. Anti-tumor effect in humanbreast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitroand in vivo. Exp Cell Res. 2011 May 1;317(8):1134-46. doi:10.1016/j.yexcr.2011.02.008. Epub 2011 Feb 19. PubMed PMID: 21338601.

4: Schultze A, Decker S, Otten J, Horst AK, Vohwinkel G, Schuch G,Bokemeyer C, Loges S, Fiedler W. TAE226-mediated inhibition of focaladhesion kinase interferes with tumor angiogenesis and vasculogenesis.Invest New Drugs. 2010 Dec;28(6):825-33. doi: 10.1007/s10637-009-9326-5.Epub 2009 Sep 26. PubMed PMID: 19784551.

5: Hehlgans S, Lange I, Eke I, Cordes N. 3D cell cultures of human headand neck squamous cell carcinoma cells are radiosensitized by the focaladhesion kinase inhibitor TAE226. Radiother Oncol. 2009 Sep;92(3):371-8.doi: 10.1016/j.radonc.2009.08.001. Epub 2009 Sep 2. PubMed PMID:19729215.

6: Lietha D, Eck MJ. Crystal structures of the FAK kinase in complexwith TAE226 and related bis-anilino pyrimidine inhibitors reveal ahelical DFG conformation. PLoS One. 2008;3(11):e3800. doi:10.1371/journal.pone.0003800. Epub 2008 Nov 24. PubMed PMID: 19030106;PubMed Central PMCID: PMC2582962.

7: Wang ZG, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T,Takaoka M, Hatakeyama S, Omori O, Ohara T, Tanabe S, Fujiwara Y,Shirakawa Y, Yamatsuji T, Tanaka N, Naomoto Y. TAE226, a dual inhibitorfor FAK and IGF-IR, has inhibitory effects on mTOR signaling inesophageal cancer cells. Oncol Rep. 2008 Dec;20(6):1473-7. PubMed PMID:19020730.

8: Beierle EA, Trujillo A, Nagaram A, Golubovskaya VM, Cance WG,Kurenova EV. TAE226 inhibits human neuroblastoma cell survival. CancerInvest. 2008 Mar;26(2):145-51. doi: 10.1080/07357900701577475. PubMedPMID: 18259944.

9: Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, KamatAA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-BeresteinG, Sood AK. Therapeutic efficacy of a novel focal adhesion kinaseinhibitor TAE226 in ovarian carcinoma. Cancer Res. 2007 Nov15;67(22):10976-83. PubMed PMID: 18006843.

10: Golubovskaya VM, Virnig C, Cance WG. TAE226-induced apoptosis inbreast cancer cells with overexpressed Src or EGFR. Mol Carcinog. 2008Mar;47(3):222-34. PubMed PMID: 17849451.

11: Shi Q, Hjelmeland AB, Keir ST, Song L, Wickman S, Jackson D, OhmoriO, Bigner DD, Friedman HS, Rich JN. A novel low-molecular weightinhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. MolCarcinog. 2007 Jun;46(6):488-96. PubMed PMID: 17219439.